Mitchell J. Bartlett

Disrupted drainage in the aging brain: Meningeal lymphatic decline as a convergent axis of vulnerability

M. Elyse Moore, Eda Karakaya, Ozgur Altinbas, Mitchell J. Bartlett et autres

The aging brain depends on coordinated fluid transport, immune surveillance, and clearance of metabolic byproducts to preserve cognitive and physiological homeostasis. While peripheral lymphatic decline is well established, growing evidence implicates brain-draining lymphatic pathways, particularly meningeal lymphatic vessels and their downstream drainage …

us, tr (code pays fourni par la source)

Early intervention with a PACAP lactoside following repetitive mild traumatic brain injury prevents persistent LHb hyperactivity and motivational deficits in male mice

Emily H. Thomas, Troy A. Smith, Lajos Szabó, William J. Flerlage et autres

Abstract Mild traumatic brain injury (mTBI) often causes long-lasting mood and motivational deficits, significantly impairing quality of life. Pituitary adenylate cyclase-activating polypeptide (PACAP) exhibits neuroprotective properties, but its role in mitigating post-mTBI circuit dysfunction remains poorly understood. Using a murine repetitive closed-head …

us (code pays fourni par la source)

ID# 1903368 Trans-spinal magnetic stimulation reduces allodynia in a common peroneal nerve injury model of neuropathic pain

Julie G. Pilitsis, Mitchell J. Bartlett, Ryan R. Mayer, Giorgio Bonmassar et autres

us (code pays fourni par la source)

Manual lymph drainage massage of the head and neck improves cognition and reduces pathological biomarkers in the 5x-FAD mouse model of Alzheimers disease

Mitchell J. Bartlett, Robert P. Erickson, Jennifer Beischel Frye, Kristian P. Doyle et autres

Alzheimer's disease (AD) affects 6.9 million people over the age of 65 in the US and is expected to double by 2060. While FDA approved immunotherapies slow cognitive decline in some individuals with AD, they do not improve cognition, are costly, and …

us (code pays fourni par la source)

Erratum: Periorbital Placement of a Laser Doppler Probe for Cerebral Blood Flow Monitoring Prior to Middle Cerebral Artery Occlusion in Rodent Models

Denali C Dickson, Mitchell J. Bartlett, Sharon Hom, Helena Willington Morrison

An erratum was issued for: Periorbital Placement of a Laser Doppler Probe for Cerebral Blood Flow Monitoring Prior to Middle Cerebral Artery Occlusion in Rodent Models. The Authors section was updated.

us (code pays fourni par la source)

Differential effects of statins on the anti-dyskinetic activity of sub-anesthetic ketamine

Mitchell J. Bartlett, Carolyn J. Stopera, Stephen L. Cowen, Scott J. Sherman et autres

Sub-anesthetic ketamine has been demonstrated to reduce abnormal involuntary movements (AIMs) in preclinical models of L-DOPA-induced dyskinesia (LID) and retrospective Parkinson's disease (PD) case reports. In this study, we examined the effects on LID of two different statins alone and in combination …

us (code pays fourni par la source)

Differential effects of statins on the anti-dyskinetic activity of sub-anesthetic ketamine

Mitchell J. Bartlett, Carolyn J. Stopera, Stephen L. Cowen, Scott J. Sherman et autres

Sub-anesthetic ketamine has been demonstrated to reduce abnormal involuntary movements (AIMs) in preclinical models of L-DOPA-induced dyskinesia (LID) and retrospective Parkinson's disease case reports. In this study, we examined the effects on L-DOPA-induced dyskinesia of two statins alone and in combination with …

us (code pays fourni par la source)

Decoupling of motor cortex to movement in Parkinson’s dyskinesia rescued by sub-anaesthetic ketamine

Abhilasha Vishwanath, Mitchell J. Bartlett, Torsten Falk, Stephen L. Cowen

Gamma-band and single-unit neural activity in primary motor cortex are involved in the control of movement. This activity is disrupted in Parkinson's disease (PD) and levodopa-induced dyskinesia (LID), a debilitating consequence of dopamine replacement therapy for PD. Physiological features of LID include …

us (code pays fourni par la source)

Symposium Highlight: BRAIN LYMPHATICS: REDISCOVERY AND NEW INSIGHTS INTO LYMPHATIC INVOLVEMENT IN DISEASES OF HUMAN BRAINS

Mitchell J. Bartlett, Robert P. Erickson, Elizabeth B. Hutchinson, Russell S. Witte et autres

The brain’s lymphatic system is comprised of a glymphatic—meningeal—cervical lymphatic vessel pathway. The study of its mechanism and pathophysiology in neurodegenerative disease has been one of the most exciting topics in basic and translational neuroscience of the last decade. However, while there …

us (code pays fourni par la source)

Cyclic Glycopeptide Analogs of Endomorphin-1 Provide Highly Effective Antinociception in Male and Female Mice

James E. Zadina, Lajos Szabó, Fahad Al‐Obeidi, Xing Y. Zhang et autres

Opioids acting at the mu opioid receptor (MOR) remain the most effective treatment for moderate to severe pain, but their use is limited by serious side effects. We have shown that a cyclized analog of endomorphin-1 provided pain relief comparable to that …

us (code pays fourni par la source)

The angiotensin (1–7) glycopeptide PNA5 improves cognition in a chronic progressive mouse model of Parkinson's disease through modulation of neuroinflammation

Kelsey Bernard, J A Mota, Paige V Wene, Mandi J. Corenblum et autres

Cognitive decline in Parkinson's Disease (PD) is a prevalent and undertreated aspect of disease. Currently, no therapeutics adequately improve this aspect of disease. It has been previously shown that MAS receptor agonism via the glycosylated Angiotensin (1-7) peptide, PNA5, effectively reduces cognitive …

us (code pays fourni par la source)

Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model

Carolyn J. Stopera, Mitchell J. Bartlett, Chenxi Liu, Alexander Esqueda et autres

Sub-anesthetic ketamine treatment has been shown to be an effective therapy for treatment-resistant depression and chronic pain. Our group has previously shown that sub-anesthetic ketamine produces acute anti-parkinsonian, and acute anti-dyskinetic effects in preclinical models of Parkinson's disease (PD). Ketamine is a …

us (code pays fourni par la source)